Clinical Trial Update: Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus [Phase 2]

View source ↗

Summary

A Phase 2a study of CG400549 for cellulitis/skin infection due to MRSA has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methicillin-resistant Staphylococcus Aureus Infections
• Skin Infection

Drugs mentioned

• CG400549

Snippet

Sponsor: CrystalGenomics, Inc. | Conditions: Skin Infection | Phase 2 | Status: COMPLETED | Results posted: 2022-07-06